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CXCR4 and CCR5 in FIV infection 
SUMMARY 
 
Feline CXCR4 and CCR5 were expressed in feline cells as fusion proteins with enhanced 
green fluorescent protein (EGFP).  Expression of the EGFP fusion proteins was localized 
to the cell membrane and surface expression of CXCR4 was confirmed using a cross-
species reactive anti-CXCR4 monoclonal antibody.  Ectopic expression of feline CCR5 
enhanced expression of either endogenous feline CXCR4, or exogenous feline or human 
CXCR4 expressed from a retroviral vector, indicating that experiments investigating the 
effect of CCR5 expression on FIV infection must be interpreted with caution. 
Susceptibility to infection with cell culture adapted strains of FIV, or to syncytium 
formation following transfection with a eukaryotic vector expressing an env gene from a 
cell culture-adapted strain of virus, correlated with expression of either human or feline 
CXCR4 whereas feline CCR5 had no effect. In contrast, neither CXCR4 nor CCR5 
rendered cells permissive to either productive infection with primary strains of FIV or 
syncytium formation following transfection with primary env gene expression vectors.  
Screening a panel of GHOST cell lines expressing diverse human chemokine receptors 
confirmed that CXCR4 alone supported fusion mediated by the FIV Env from cell 
culture-adapted viruses. CXCR4-expression was up-regulated in GHOST cells co-
expressing CXCR4 and CCR5, or CXCR4, CCR5 and CCR3 and susceptibility to FIV 
infection could be correlated with the level of CXCR4 expression. The data suggest that 
β-chemokine receptors may influence FIV infection by modulating the expression of 
CXCR4.  
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INTRODUCTION 
Infection of the domestic cat with feline immunodeficiency virus induces an illness 
similar to AIDS in HIV-infected human beings (39, 48).  Although infection with FIV  is 
accompanied by a gradual decline in the number of CD4+ lymphocytes (2), the feline 
homologue of CD4 does not appear to act as a primary binding receptor for infection with 
the virus and ectopic expression of feline CD4 on feline cells does not confer 
susceptibility to infection with FIV (36). Further, the expression of CD4 in the domestic 
cat is restricted to helper T cells and their thymic precursors and, unlike human CD4, 
feline CD4 is not expressed on cells of the monocyte / macrophage lineage (1). Previous 
studies have demonstrated that feline monocyte/macrophage lineage cells, and a range of 
other CD4-negative cells (CD8+ lymphocytes, B lymphocytes, astrocytes and Schwann 
cells) are susceptible to infection with FIV (6, 14).    If the primate lentiviruses evolved 
the use of CD4 as high affinity binding receptor in order to target the viruses more 
efficiently to T helper lymphocytes and monocyte/ macrophages, it is possible that FIV 
represents a more primitive ancestor of HIV, encoding fewer regulatory genes (the FIV 
genome lacks nef, vpu and vpr open reading frames) and lacking the specific targeting of 
CD4+ cells. As such, by studying FIV, it may be possible to identify the viral 
determinants that render the feline and primate lentiviruses immunodeficiency-causing 
rather than inducing chronic inflammatory conditions as typified by caprine arthritis 
encephalitis virus (CAEV) and (Maedi-Visna virus) MVV. With the discovery of the role 
of seven transmembrane domain superfamily (7TM) molecules in infection with the 
primate lentiviruses, a possible link between the feline and primate lentiviruses was 
uncovered. Subsequently, it was revealed that FIV uses the chemokine receptor CXCR4 
 3
CXCR4 and CCR5 in FIV infection 
as a receptor for infection (53); ectopic expression of CXCR4 confers susceptibility to 
infection with FIV (50, 55) and the FIV envelope glycoprotein binds CXCR4 with a high 
affinity (19). Further, FIV infection is inhibited by the natural ligand for CXCR4 (19) 
(SDF-1, CXCL12)  and CXCR4 antagonists such as met-SDF, AMD3100 and ALX-
404C (16, 43, 51).  Given the importance of the virus-receptor interaction in determining 
the cell tropism of a virus, the shared usage of CXCR4 as a cellular receptor by HIV and 
FIV represents a potential means by which the viruses may induce similar pathologies. 
 The principal chemokine receptors utilized by HIV as co-receptors for infection 
are CXCR4 and CCR5 (a receptor for the β-chemokines RANTES, MIP-1α and MIP-1β) 
(3, 12, 15, 18). While a diverse range of other 7TM molecules has been shown to act as 
co-receptors for the primate lentiviruses (reviewed in  (8)) the role of these additional 
molecules in the pathogenesis of AIDS remains unclear. While CCR5 appears to be the 
co-receptor utilized by the majority of strains HIV early in infection, usage of CXCR4 as 
a co-receptor is more frequent with disease progression (45).  The shift in co-receptor 
usage from CCR5 to CXCR4 (formerly identified as non-syncytium-inducing (NSI) and 
syncytium-inducing (SI) respectively) with disease progression raises the question as to 
whether usage of CXCR4 as a viral receptor arises a result of disease progression or 
whether it hastens disease progression.  
 Previous studies have demonstrated that during the early phase of infection with 
FIV, the major reservoir of infected cells in peripheral blood is CD4+ lymphocytes. In 
contrast, in chronic infection both CD8+ lymphocytes and B  lymphocytes are infected 
suggesting a shift in viral tropism with prolonged infection (10, 11, 17).  These data 
provide compelling evidence for the existence of viruses with distinct cell tropisms in 
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infected cats, analogous to CCR5 and CXCR4-dependent viruses in HIV-infected 
individuals. Conflicting data have been presented regarding the usage of CCR5 as a co-
receptor by FIV. Early studies demonstrated that ectopic expression of CCR5 did not 
confer susceptibility to infection with cell culture adapted strains of FIV (50) while 
studies on the inhibition of FIV infection with β-chemokines have provided little data to 
support a role for CCR5 in FIV infection, since RANTES, MIP-1α and MIP-1β failed to 
inhibit FIVGL8 infection of Mya-1 cells (19) and displayed only a 20-40% reduction in 
FIVPPR  infection of T cells (24). In contrast, a separate study showed that anti-human 
CCR3 and CCR5 could inhibit infection of human PBMC with FIV, suggesting that not 
only could FIV utilize CCR5 for infection, but that it could use human CCR3 and CCR5 
as co-receptors for infection (22).  Moreover, recent studies have suggested that the V1-
CSF isolate of FIV requires co-expression of human CCR5 and CCR3 for infection of 
cells expressing human CXCR4 and have proposed that human CCR3 and CCR5 act as 
co-receptors for FIV infection (23). The aim of this study was to define further the role of 
CXCR4 and  CCR5 in FIV infection. We demonstrate that ectopic expression of CCR5 
enhances cell surface expression of CXCR4, and in doing so, may enhance susceptibility 
of CCR5-expressing cells to infection with CXCR4-dependent strains of FIV. 
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Materials and Methods 
Plasmids  and cDNA cloning.   Feline CXCR4 (U63558) has been described 
previously.  Feline CCR5 cDNAs (U92796) was obtained from J. Elder (Scripps 
Research Institute, La Jolla, CA). pCI-VSV-G was obtained from G. Nolan, Stanford 
University, USA. pHIT60 was obtained from A. Kingsman, Oxford Biomedica, Oxford, 
UK.  cDNAs were sub-cloned into the  EGFPN1 vector (Clontech Laboratories Inc., Palo 
Alto, USA.) as EcoRI/BamHI fragments creating an N-terminal fusion with EGFP. Sub-
cloning of the cDNAs were performed using the polymerase chain reaction (PCR,  Hi-
Fidelity PCR system, Roche Diagnostics Ltd., Lewes, UK ) and a GeneAmp PCR system 
9700 thermal cycler (PE Applied Biosystems, Warrington, UK), with oligonucleotide 
primers carrying the appropriate restriction sites; amplification of CXCR4 used primers 
5’-GCGAATTCACCATGGACGGGTTTCGTATATAC-3’ and 5’-
CGGTGGATCCGAGGAGTGAAAACTTGAAGA-3’ while CCR5 was amplified with 
primers 5’-GCGAATTCACCATGGATTATCAAGCCACGAG-3’ and 5’-
CGGTGGATCCAAGCCGACAGAGATTTCCTG-3’. The CXCR4 and CCR5/EGFP 
fusion products were then sub-cloned as SalI/HpaI fragments into the pDONAI retroviral 
vector (Takara Shuzo Co. Ltd., Shiga, Japan) by re-amplification using the primers 5’-
GCGTCGACGCTAGCGCTACCGGACTCAGATCT-3’ and 5’-
TTGTTAACGCGGCCGCTTTACTTGTACAGCTC-3’. 
 FIV env genes were amplified from the GL8414 (21),  PPR (40),  PETF14  (37), and 
the GL8EK  (21) molecular clones by PCR as above using the oligonucleotide primers 5’-
GGGTCGACACCATGGCAGAAGGGTTTGCAGCA-3’ and 5’-
GGGCGGCCGCCATCATTCCTCCTCTTTTTCAGAC-3’, incorporating SalI and NotI 
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restriction sites, and cloned into the eukaryotic expression vector VR1012 (Vical 
Incorporated, San Diego, USA).  The nucleic acid sequences of  all cDNAs subcloned by 
HiFidelity PCR were determined using Big Dye Terminator Cycle Sequencing kit 
Version 2 (ABI Prism, Applied Biosystems) and an Applied Biosystems 3700 capillary 
sequencer. 
Viruses and cell lines.  All cell culture media and supplements were obtained 
from Invitrogen Life Technologies Ltd. (Paisley, UK). Adherent cell lines were 
maintained in Dulbecco’s modification of minimum essential medium (DMEM) 
supplemented with 10% foetal bovine serum (FBS), 2mM glutamine, 0.11mg/ml sodium 
pyruvate, 100 IU/ml penicillin and 100 μg/ml streptomycin (DMEM).  GHOST(3) cell 
lines (34) were obtained from the MRC AIDS directed programme.  AH927 and Ghost 
cells expressing feline CXCR4 and CCR5, or human CXCR4, were generated by 
transduction with the retroviral vectors pDONAI (Takara Shuzo Co. Ltd.) or pBabePuro 
(33) bearing the appropriate cDNA.  Murine leukaemia virus (MLV) pseudotypes 
carrying the pDONAI or pBabePuro retroviral vectors were prepared by transfection of 
HEK 293T cells with the retroviral vector in conjunction with pHIT60 (47) (encoding the 
MLV gagpol)  and  pCI-VSV-G  (encoding the vesicular stomatitis G protein) at a 1:1:1 
ratio using Superfect transfection reagent (QIAGEN Ltd., Crawley, UK).  Supernatants 
were collect 48 hours post-transfection, filtered at 0.45μm, and used to transduce the 
target cell lines at an approximate multiplicity of infection of 1.0 (assessed by 
transducing a parallel culture with pseudotypes bearing a retroviral vector encoding a 
lacZ reporter gene). Two days post-transduction the target cells were sub-cultured and re-
seeded in culture medium supplemented with 800μg/ml G418 (Geneticin, Life 
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Technologies) or 2.5μg/ml puromycin (Sigma).  Cells were maintained in the selective 
antibiotic until stably transduced populations outgrow the cultures.  GHOST-FX4 and 
FR5 were generated by transduction of GHOST cells with feline CXCR4 or CCR5 in the 
retroviral vector pBabepuro (33).  
The IL2-dependent feline T cell lines Mya-1 (32), Q201 (52) and peripheral blood 
mononuclear cells were maintained in RPMI-1640 medium supplemented with 10% FBS, 
2mM glutamine, 100 IU/ml penicillin,100 μg/ml streptomycin, 5 x 10-5 M 2-
mercaptoethanol and 100 IU/ml recombinant human interleukin 2  (RPMI).   Virus stocks 
were prepared from molecular clones of  FIV (GL8414 (21),  PPR (40),  PETF14  (37), 
TM2 (31) and the GL8EK  (21)).  FIV-B-2542 was obtained from S. Vandewoude, 
Colorado State University, Fort Collins, CO, USA) Molecular clones were transfected 
into the human epithelioid cell line HEK 293T using Superfect transfection reagent 
(QIAGEN Ltd.). 48 hours post transfection, supernatants were harvested, 0.45μm filtered 
and used to infect the IL2-dependent feline T cell line Mya-1 (32).  The infected cultures 
were monitored visually for cytopathicity and for the production of FIV p24 by enzyme-
linked immunosorbent assay (ELISA, PetCheck FIV antigen ELISA, IDEXX Corp., 
Portland, Maine, USA). Supernatants were collected at peak cytopathicity / p24 
production, 0.45μm filtered, dispensed into 1ml aliquots and stored at –70oC.  
 The growth of FIV strains in vitro was assessed by infection of the target cell line 
with virus stocks prepared in IL2-dependent T cells (Mya-1 cells). Cells were incubated 
with a matched tissue culture infective dose of virus for one hour at 37oC, washed twice 
with phosphate buffered saline, fed with fresh culture medium and maintained in culture 
for 7-10 days.  Supernatants were collected every three days and assayed for the 
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production of p24 (PetCheck FIV antigen ELISA, IDEXX Corp.) or reverse transcriptase 
(RT) using Lenti-RT non-isotopic RT assay kit (Cavidi Tech., Uppsala, Sweden).   
 
Antibodies and flow cytometry. Antibodies were used either un-conjugated or 
conjugated to either phycoerythrin (PE) or fluorescein isothiocyanate (FITC). Anti- 
CXCR4 (human-specific) antibody 12G5 was obtained from James Hoxie, University of 
Pennsylvania, USA. Anti-CXCR4 (human/feline cross-reactive) #44717 and #44708 
(human CXCR4-specific) and anti-human CCR5 #45519 were obtained from Dr. Monica 
Tsang (R&D systems, Minneapolis, USA). Un-conjugated primary antibodies (IgG 
isotype) were detected using FITC or PE-coupled F(ab’)2 fragment of sheep anti-mouse 
IgG whole molecule (Sigma, Poole, UK). Samples were analysed on   Beckman Coulter 
Epics Elite and EPICS XL flow cytometers and 10,000 events were collected for each 
sample. Data were analysed using Expo32 ADC software (Applied Cytometry Systems, 
Sheffield, U.K.). In the analysis of GHOST cells expressing CXCR4 or CCR5, 
percentages were calculated relative to the GHOST cells parent cell lines by overlaying 
histograms and applying Overton analysis (38) using the Expo32 ADC software package. 
 
In vitro expression of env genes.  The expression of functional Env proteins 
from the VR1012 expression conctructs was confirmed by  immunofluorescence using 
anti-FIV Env monoclonal antibody (vpg71.2).  Immunofluorescence was performed on 
transfected HEK 293T cells at 72 hours post-transfection following fixation with ice-cold 
methanol.  Fixed cells were re-hydrated using phosphate buffered saline containing 1.0% 
bovine serum albumin and 0.1% azide (PBA). The cells were then incubated with either 
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1μg of vpg71.2 or an isotype-matched control for 30 minutes on ice, washed twice with 
PBA by centrifugation, and then incubated with FITC-coupled F(ab’)2 fragment of sheep 
anti-mouse IgG whole molecule (Sigma Ltd.) on ice for a further 30 minutes. Finally, the 
cells were washed twice with PBA and then examined on a Leica UV microscope or by 
flow cytometry on an EPICS Elite flow cytometers (10,000 events collected in 
Listmode).  To assess the fusogenicity of the FIV Env proteins, AH927 or Ghost cells 
were transfected with the VR1012-Env constructs using Superfect (QIAGEN) and 
incubated for 48 hours at 37oC.  The cells were then fixed and stained with 1% methylene 
blue/ 0.2% basic fuchsin in methanol. Syncytia were enumerated by light microscopy 
using a x12.5 Leitz periplan eyepiece with a 6.5x9 graticule, three separate fields being 
counted per well, each well in duplicate.  Syncytia were scored as cells with five or more 
nuclei. 
 
Detection of viral entry using PCR.  Ghost or AH927 cells were seeded in 6-
well culture plates at 1.5x105 cells per well and incubated overnight at 37oC. Cells were 
infected with PETF14 or GL8414 for 1 hour at 37oC, rinsed twice with phosphate buffered 
saline and then fed with fresh culture medium. Following overnight incubation at 37oC 
the cells were removed from the culture plates using trypsin-EDTA, pelleted and DNA 
prepared using a QIAamp DNA blood kit (QIAGEN).   0.5mg of DNA was then used in 
semi-quantitative polymerase chain reactions (PCR) in which either an 871bp FIV gag 
gene product was amplified using the primers 5’-GGG ATT AGA CAC TAG GCC ATC 
TA-3’ and 5’-GAC CAG GTT TTC CAC ATT TAT TA-3’ or a control cellular DNA for 
β-actin was amplified using the primers 5’-ATC TGG CAC CAC ACC TTC TAC AAT 
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GAG CTG CG-3’ and  5’-CGT CAT ACT CCT GCT TGC TGA TCC ACA TCT GC-3’. 
Reactions were denatured at 94oC for 3 min. followed by 30 cycles of denaturation at 
94oC for 30sec., annealing at 50oC for 1 min. and extension at 72oC for 1min., with a 
final extension of 10min. at 72oC. All reactions were performed using HiFidelity PCR 
reaction mix (Roche) as per manufacturer’s instructions on a GeneAmp PCR system 
9700 (Perkin Elmer). 
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RESULTS 
 
Ectopic expression of feline CXCR4 and CCR5.   In order to examine further the role 
of CXCR4 and CCR5 in  FIV infection, we developed cell lines that would stably express 
either molecule as C-terminal fusion proteins with enhanced green fluorescent protein 
(EGFP), enabling the expression of CXCR4 and CCR5 to be evaluated by flow cytometry 
and UV microsopy.  The feline CXCR4-EGFP and CCR5-EGFP genes were subcloned 
into the pDONAI retroviral vector, packaged into murine leukaemia virus (MuLV) 
particles bearing the vesicular stomatitis virus (VSV) G-protein and used to transduce the 
feline cell lines AH927, CrFK and 3201, and the murine cell line 3T3.  EGFP alone was 
included as the control.  Figure 1 illustrates the results of flow cytometric analyses on the 
transduced AH927 cells (Fig. 1 a to c).  EGFP expression was detected on each of the 
transduced cell lines, the highest mean fluorescence intensity being observed in the cells 
transduced with the retroviral vector bearing EGFP alone (mean fluorescence = 101.7, 
99.2% positive). In contrast, while the majority of the cells transduced with CXCR4-
EGFP or CCR5-EGFP expressed EGFP (97.3% and 91.1%),  the mean fluorescence 
intensity was significantly lower (CXCR4-EGFP mean fluorescence = 6.1, CCR5-EGFP 
mean fluorescence = 3.7).  UV microscopy revealed that while the fluorescence in the 
EGFP control was diffuse and cytoplasmic (Fig. 1d), fluorescence in the cells transduced 
with CXCR4-EGFP or CCR5-EGFP was largely peri-nuclear and membrane associated 
(Fig 1e and 1f), consistent with the predicted localisation of the  EGFP-tagged chemokine 
receptors. Similar results were obtained with the 3T3, CrFK and 3201 cell lines (not 
shown).  
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We next examined the expression of CXCR4 at the cell surface of the transduced 
AH927 cells using anti-CXCR4 monoclonal antibody. Previously we identified anti-
human CXCR4 monoclonal antibodies that cross-reacted with feline CXCR4 (19).  Using 
two-colour flow cytometry we observed that a minority of the AH927 cells (4.6%) 
expressed CXCR4. A similar level of CXCR4 expression was detected on the cells 
transduced with EGFP alone (E, 4.8%, Fig. 2b). In contrast, 51.6% of the CXCR4-EGFP 
cells (FX4E) were CXCR4 positive (Fig. 2d) confirming that the CXCR4–EGFP fusion 
protein was expressed at the cell surface. 30.4% of the CXCR4-EGFP cells were EGFP 
positive but surface CXCR4-negative, suggesting that this represented intracellular 
CXCR4-EGFP. Finally, we examined at surface CXCR4 expression on the CCR5-EGFP 
transduced cells (FR5E). Surprisingly, transduction with the CCR5-EGFP expressing 
vector had increased surface expression of CXCR4 to 10.4%. Given that only 4.8% of the 
cells transduced with EGFP expressed surface CXCR4, these data suggested that ectopic 
expression of CCR5 may up-regulate endogenous CXCR4 expression on the AH927 
cells.  
The CCR5-EGFP cells were used to screen a range of anti-human CCR5 
monoclonal antibodies (2D7, Leukosite Inc.; 45511, 45517, 45519, 45523, 45529, 45531 
and 45533, R&D Systems),  however,  no cross-reactivity was detected (data not shown). 
 
Up-regulation of CXCR4 following ectopic expression of CCR5.  In order to 
investigate further the possible up-regulation of CXCR4 following CCR5 expression we 
examined the effects of transducing the AH927-derived cell lines expressing either EGFP  
(E-P) or the feCXCR4 and feCCR5-EGFP fusion proteins with a second series of 
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retroviral vectors expressing feline CXCR4 (FX4P), feline CCR5 (FR5P) or human 
CXCR4 (HX4P) from retroviral vectors carrying a selectable marker for puromycin 
resistance. Parallel cultures were transduced with the vector carrying puromycin 
resistance alone (P) as a control. CXCR4 expression was measured by flow cytometry 
using either an antibody recognizing a common epitope shared between feline and human 
CXCR4 (44718) or a human CXCR4-specific antibody (12G5).   Transduction with the 
puro vector and selection in puromycin alone did not alter expression of CXCR4, 4.7% of 
cells in the control group “E-P” were CXCR4-positive representing basal endogenous 
CXCR4 expression (Fig.3a). Transduction of the EGFP control cells with FX4P (Fig. 3b) 
and HX4P (Fig. 3d) elevated CXCR4 expression to 26.1% and 80.1% respectively. 
Transduction with FR5P elevated CXCR4 (Fig. 3c) expression to 11.3%, confirming the 
previous observations with FR5E that ectopic CCR5 expression enhances endogenous 
CXCR4 expression.  
 We next examined CXCR4 expression on FR5E cells transduced with P (Fig. 3e), 
FX4P (Fig. 3f), FR5P (Fig. 3g) or HX4P (Fig. 3h). FR5E cells transduced with the puro 
vector alone continued to express enhanced levels of CXCR4 (28.7% of FR5E-P were 
CXCR4-positive compared with 4.7% of E-P). That 28.7% of the FR5E-P cells were 
CXCR4 positive (Fig. 3E) compared with 10.4% of FR5E (Fig. 2F) may reflect the 
higher passage number of the FR5E-P cells following selection in puromycin-containing 
medium and underlines the importance of the E-P control (4.7% positive) transduced and 
maintained in parallel.   Following transduction with FX4P, 70.5% of FR5E-FX4P cells 
were CXCR4-positive. Compared with the E-FX4P (26.1%), the elevated expression of 
CXCR4 on FR5E-FX4P indicated that stable expression of feline CCR5 enhanced the 
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expression of both endogenous and ectopically expressed CXCR4. Transduction of FR5E 
with FR5P did not enhance CXCR4 expression further (FR5E-FR5P 27.8% CXCR4-
positive compared with FR5E-P 28.7%. Similarly, transduction with HX4P did not 
enhance CXCR4-expression further (FR5E-HX4P 75.7% compared with E-HX4P 
80.1%). These findings indicate that transduction with a feline CCR5 – expressing vector 
will a) increase surface expression of endogenous CXCR4 and b) enhance expression of 
ectopically expressed CXCR4 following subsequent transduction with a CXCR4-
expressing vector.  FX4E transduced with P (Fig. 3i), FX4P (Fig. 3j), FR5P (Fig. 3k) or 
HX4P (Fig. 3l) expressed similar levels of CXCR4 (86.4%, 87.2%, 88.3%, 86.7% 
respectively) suggesting that a maximal level of CXCR4 expression had been achieved 
and could not be increased further. 
Using the anti-human CXCR4-specific monoclonal antibody 12G5, we examined 
the expression of human and feline CXCR4 on HX4P-transduced AH927- E, FR5E or 
FX4E cells (Figure 4). While 49.5% of control AH927-E cells transduced with HX4P 
were revealed as CXCR4-positive following staining with the 12G5 antibody (Fig. 4b)), 
75.7% of FR5E (Fig. 4d) and 83.9% of FX4E (Fig. 4f) were positive for human CXCR4 
following transduction. These findings confirm our previous findings showing enhanced 
human CXCR4 expression in cells expressing CCR5. Further, as prior transduction with 
feline CXCR4 also enhanced expression of human CXCR4, the data demonstrate that the 
effect is not CCR5-specific and that ectopic expression of feline CXCR4 will augment 
human CXCR4 expression.  
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Effects of CXCR4 and CCR5 expression on  FIV infection. CXCR4 has been 
widely implicated in infection with FIV (13, 16, 41, 43, 50, 53, 55). In contrast, a single 
study suggested a role for human CCR5 and CCR3 in infection with FIV (22). Having 
generated cell lines that stably express feline CXCR4 and CCR5, we next asked whether 
these cells would be rendered permissive for either Env-mediated syncytium formation or 
cell-free virus infection with the GL8414 and PETF14 clones (representing primary and 
CrFK-adapted strains of virus respectively). Each of the AH927 cell lines expressing 
feline CXCR4, feline CCR5 or human CXCR4 were either transfected with the 
eukaryotic expression vector VR1012 expressing the GL8414 or PETF14 env genes, or 
infected with cell-free virus supernatant containing either the GL8414 or PETF14 viruses 
(Fig. 5). Previous studies have demonstrated that infection of AH927 cells by FIV is 
blocked at the level of viral entry and that productive infection will occur following 
successful viral entry (21). Syncytium formation was monitored by light microscopy and 
scored + or - while productive infection was monitored by non-isotopic reverse 
transcriptase assay (expressed as A650nm). There was a good correlation between both 
syncytium formation in PETF14 Env transfected cells, PETF14 infection and ectopic 
expression of either feline or human CXCR4. In contrast, CXCR4 expression alone did 
not render AH927 cells permissive for either GL8414 Env – mediated fusion or infection 
with GL8414 virus (similar findings were obtained with the primary PPR strain of FIV, 
data not shown).  Feline CCR5 expression alone was insufficient to render cells 
permissive to infection with PETF14 or GL8414.  Moreover, co-expression of feline CCR5 
with either feline CXCR4 or human CXCR4 did not render the cells permissive to 
infection with GL8414.  Ectopic expression of CXCR4 or CCR5 did not render the AH927 
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cells permissive to infection with the primary strain clade B viruses TM2 or B2542 (data 
not shown). Thus feline CCR5 expression, either alone or co-expressed with feline 
CXCR4 or human CXCR4 was insufficient to render cells permissive to fusion / 
productive infection with four primary strains of FIV.  
 
Feline or human CCR5 do not support fusion mediated by envelope 
glycoproteins from primary or cell culture adapted strains of FIV.  Given that a 
previous study had suggested a role for human CCR5 or CCR3 in FIV infection (22), we 
examined the effect of transfecting chemokine receptor-expressing  cells with expression 
vectors bearing envelope glycoproteins from primary or cell culture adapted strains of 
FIV.  Following expression of the PETF14 or GL8EK (a version of GL8 bearing an E407K 
mutation in the V3 loop  (21)) envelopes in GHOST cells expressing either feCXCR4 or 
feCCR5, or human CXCR4, CCR1, CCR2, CCR3, CCR4, CCR5, CCR8, Bonzo, BOB, 
EB-1 or V28, syncytia were observed in the cells expressing feline or human CXCR4 but 
in no other cell line (Figure 6.). Similarly, the primary envelopes GL8414 or PPR did not 
induce syncytium formation in any of the cell lines tested.  The cells co-expressing 
human CXCR4 and CCR5 (X4R5), or huCXCR4,  CCR5 and CCR3 (X4R5R3) appeared 
to display enhanced syncytium formation following transfection with the PETF14 or 
GL8EK Envs (Fig. 6), however they did not support syncytium formation following 
transfection with the GL8414 or PPR Envs.  Further, the panel of GHOST cell lines 
remained refractory to infection with HIV pseudotypes bearing the GL8414 or PPR 
envelopes and carrying a luciferase reporter gene (9) (data not shown).  Given that 
ectopic expression of feline CCR5 enhances cell surface expression of CXCR4, we 
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postulated that the enhanced syncytium formation mediated by the PETF14 and GL8EK 
Envs  in X4R5 and X4R5R3 cell lines may reflect enhanced CXCR4 expression in these 
cell lines. We therefore analysed CXCR4 and CCR5 expression on the GHOST cell lines 
by flow cytometry (Fig. 7.).  GHOST R5 (Fig. 7a) cells expressed low levels of CCR5 
(6.97%). CCR5 expression was increased in GHOST X4R5 (28.27%) and more markedly 
in X4R5R3 (66.53%). Thus co-expression of CXCR4 or CXCR4 and CCR3 in GHOST 
R5 cells significantly enhanced CCR5 expression. Similar findings were observed for the 
expression of CXCR4 (Fig. 7b) with X4R5R3 cells expressing more CXCR4 (86.02%) 
than cells co-expressing CXCR4 and CCR5 (77.54%), or CXCR4 alone (73.26%).  
Finally, we compared the expression of CXCR4 on Ghost cells transduced with a 
puromycin resistance vector alone (control), CCR5 (R5) or selected for high levels of 
CCR5 expression (Hi5). As shown in Figure 7c, the Hi5 cells expressed more CXCR4 
(33.9%) than the R5 cells (21.3%) or the control cells (19.1%), confirming that by 
selecting for human CCR5 expression, CXCR4 expression is also increased. The data 
suggest an alternative explanation for the enhanced syncytium formation in the cells co-
expressing more than one chemokine receptor, this being up-regulation of surface 
CXCR4 expression.  We next asked whether the enhanced syncytium formation in the 
X4R5 and X4R5R3 cells correlated with enhanced susceptibility to infection with PETF14 
or GL8414 (Fig. 8). Given that there is a post-entry block to the replication of FIV in 
Ghost cells, viral entry into the GHOST cell lines was assessed by PCR for FIV gag 
DNA at 24 hours post-infection.  Infection of GHOST cells was enhanced significantly 
by co-expression of  CXCR4 with CCR5 (X4R5) or CCR5 and CCR3 (X4R5R3) (Fig. 
8a). Further, expression of CCR5 alone enhanced infection with PETF14 relative to the 
 18
CXCR4 and CCR5 in FIV infection 
control cells (transduced with puro vector alone). Similar findings were observed with 
GL8414 although, as expected, infection was extremely inefficient compared to PETF14.  
Expression of X4, X4R5, X4R53 or R5 alone increased viral entry relative to the 
controls.   We compared (in parallel) the susceptibility of the AH927-derived cell lines 
FX4E, FR5E or E described above to infection with PETF14 or GL8414. While a strong 
product was amplified from FX4E infected with PETF14, extremely faint products were 
present in FR5E and E cells infected with PETF14, or FX4E, FR5E or E infected with 
GL8414.  The finding that GL8414 enters the human cell line Ghost more efficiently than 
the feline cell line AH927 is consistent with our previous findings which demonstrated 
that human CXCR4 supports fusion mediated by the FIV Env protein more efficiently 
than feline CXCR4 (50). Accordingly, AH927 cells expressing human CXCR4 support 
FIV infection more efficiently than cells expressing feline CXCR4 (data not shown). 
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DISCUSSION 
 
In this study, we examined the effects of feline CXCR4 and CCR5 expression on 
FIV infection. In order to ensure that expression of the chemokine receptors could be 
monitored, they were expressed as C-terminal fusion proteins with the N-terminus of 
enhanced green fluorescent protein (EGFP).  The CXCR4 and CCR5 EGFP fusion 
proteins were found to target the EGFP to the cell membrane and to be expressed at the 
cell surface (CXCR4).  Using cells stably transduced with CXCR4-EGFP (FX4E) or 
CCR5-EGFP (FR5E) we demonstrated that CXCR4 expression was essential for 
infection of AH927 cells with the cell culture adapted strain of PETF14 but did not confer 
susceptibility to infection with the primary strain GL8414.  In contrast, CCR5 expression 
had no effect on susceptibility to infection with any of the four strains of FIV tested.  In 
subsequent experiments we have found that ectopic expression of feline CCR5-EGFP on 
the feline lymphosarcoma cell line 3201 did not render the cells permissive to infection 
with primary strains of FIV (data not shown). 
Previous studies have suggested that human CCR5 and CCR3 are involved in 
infection of human PBMC with FIV (22). These studies were based on the ability of 
monoclonal antibodies against human CCR5 and CCR3 to inhibit infection of human 
PBMC with FIV. In our studies we found no evidence for a role for feline CCR5 in FIV 
infection; ectopic expression of CCR5 does not confer susceptibility to infection with 
primary strains of FIV and infection with primary strains of FIV is not inhibited by β-
chemokines  (19) or viral chemokine homologues (v-MIP, data not shown).  A number of 
studies have failed to show significant inhibition of FIV infection by β-chemokines (13, 
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19).  RANTES may either enhance the binding of FIV SU to feline cells (13) or have 
partial inhibitory activity on FIV infection (24).  Given that feline CCR5 and human 
CCR5 share only 82.6% amino acid similarity (76.6% identity), this difference being 
borne out by the failure of numerous anti-human CCR5 antibodies to recognize feline 
CCR5, the data would not predict a direct role for  human CCR5 in FIV infection. 
Indeed, infection with the majority of FIV isolates studied to date can be blocked by the 
CXCR4 antagonist AMD3100 ( (16, 43) and unpublished observations). In this study, we 
have demonstrated that ectopic expression of feline or human CCR5 leads to up-
regulation of cell surface CXCR4 expression.  Thus it is possible that modulating CCR3 
or CCR5 expression may affect the expression of a known receptor for FIV, namely 
CXCR4.   
The up-regulation of CXCR4 expression following ectopic expression of CCR5 
has implications for experiments in which chemokine receptor usage by lentiviruses is 
evaluated in vitro.  For example, a virus that is capable of using CXCR4 efficiently may 
infect cells transfected or transduced with a CCR5-expressing construct if CXCR4 is up-
regulated to a sufficient degree.  Accordingly, we found that GHOST cells expressing β-
chemokine receptors expressed enhanced levels of CXCR4 and were more susceptible to 
fusion mediated by PETF14 or GL8EK Envs, and supported viral entry more efficiently 
following challenge with either the PETF14 or GL8414 strains of FIV.  Our findings 
indicate that the ectopic expression of CCR3 and CCR5 may modulate CXCR4 
expression, analogous to the modulation of feline CXCR4 expression by phorbol 
myristate acetate (PMA) or stromal derived factor-1 (SDF-1) (19).  Overnight incubation 
with SDF-1 or PMA resulted in up-regulation of CXCR4 expression, enhancing 
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susceptibility to FIV infection (19).  Previous studies have indicated that chemokine 
receptors may form homodimers and heterodimers and that dimerisation of chemokine 
receptors is a critical step in the signaling process (27, 30, 44).  Indeed, the formation of 
heterodimers between CXCR4 or CCR5 and CCR2V64I  (a mutant of CCR2 associated 
with a delay in progression to AIDS (46)) has been  proposed as a mechanism by which 
CCR2V64I prevents HIV-1 infection (28).  Moreover, HIV-1 infection is blocked by 
dimerisation of CCR5 (49) and the formation of heterodimers between CCR2 and CCR5 
triggers distinct signaling pathways from either CCR2 or CCR5 expressed as 
homodimers (29, 44).  Recently, CCR5 was found to exist in several active states and 
oligomerisation of CCR5 resulted in internalization of the receptor via a distinct pathway 
to that induced by the receptor’s agonist (5), suggesting that the regulation of chemokine 
receptor expression is complex and dependent on many variables.  Thus, the up-
regulation of endogenous feline CXCR4 or exogenous human CXCR4 following ectopic 
expression of feline CCR5 may affect the sensitivity of the target cells to infection with 
FIV, or to the antagonistic effects of chemokines on FIV infection.  
Previously, it was observed that human CCR3 or CCR5-expressing cells 
supported infection with the V1CSF strain of FIV, and yet there was an absolute 
requirement for CXCR4 expression for infection to occur and anti-CXCR4 antibody 
completely ablated infection (23).  Further, although ectopic expression of human CCR3 
and CCR5 on feline cells (CrFK) enhanced infection with FIV strain V1CSF, the parent 
cell line (CrFK) also supported infection at a lower level in the absence of human CCR3 
or CCR5 (23).  Either CrFK cells express a chemokine receptor in addition to CXCR4 
that substitutes for human CCR3/CCR5, or V1CSF is capable of using CXCR4 alone as a 
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receptor inefficiently.  That the V1CSF strain infects GHOST cells expressing CCR3 and 
CCR5 but not CXCR4 alone, and yet infection is blocked completely by anti-CXCR4 
antibody, is intriguing and may suggest the use of a CXCR4-containing receptor complex 
for infection as has been suggested (23).  We have found that ectopic expression of 
human β-chemokine receptors in human or feline cells may increase the expression of 
endogenous CXCR4, increasing the susceptibility of the cells to infection with X4-
dependent viruses. Infection of GHOST cells with FIVPET or FIVGL8 correlates with the 
expression of human CXCR4 within these cells and is consistent with the preference for 
human CXCR4 over feline CXCR4 as a co-factor for Env-mediated fusion by cell culture 
adapted strains of FIV  (50). The contribution of CXCR4 up-regulation to infection with 
the V1CSF strain will require further investigation, however, it is possible that the 
V1CSF isolate reflects a novel strain of FIV with a broad preference for chemokine 
receptor usage,  analogous to dual-tropic strains of HIV.  Determination  of the 
prevalence of such strains of virus in the cat population clearly merits further 
investigation and comparison with established, highly characterized, strains of FIV. 
The mechanism by which co-expression of one chemokine receptor up-regulates 
the surface expression of another chemokine receptor remains to be established.  Previous 
studies have demonstrated that 7TM molecules are capable of forming both homodimers 
and heterodimers on the cell surface.  Further, engagement of chemokine receptors by 
either natural or synthetic ligands can induce receptor down-regulation. Chemokine 
receptors such as CCR5 distribute asymmetrically in polarized cells, associating with 
membrane microdomains (26), structures of importance in membrane trafficking and 
signal transduction. HIV infection is thought to proceed following an interaction with 
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chemokine receptors clustered within these regions (25) and the co-localisation of CD4 
with CXCR4 and CCR5 within these regions is required for productive infection  of PM1 
T cells (42).   If CXCR4 and CCR5 or CCR3 exist as heterodimers, or are localized to 
microdomains on the cell surface, it is conceivable that anti-CCR3 and CCR5 antibodies 
may interfere with viral access to CXCR4 or disrupt the membrane microdomains 
essential for viral entry.   Indeed, monoclonal antibodies recognizing molecules 
associated with lipid rafts inhibit syncytium formation mediated by HTLV-1 (35). 
Moreover, since CD9 (a TM4 superfamily molecule) is also associated with lipid rafts 
(7), the disruption of membrane microdomains by anti-CD9 antibodies may account for 
previous conflicting results in which anti-CD9 antibodies blocked infection with FIV and 
ectopic expression of feline CD9 enhanced susceptibility to FIV infection, and yet, 
ectopic expression of CD9 was insufficient to render non-susceptible cells permissive for 
FIV infection   (20, 54). 
The results of this study demonstrate that while FIV infection of the domestic cat 
provides a unique opportunity to study an immunodeficiency-causing lentivirus in its 
natural host,  resolution of the role of β−chemokine receptors in FIV infection will be of 
importance to our understanding of the evolution of virulence in lentiviruses. In this way 
the cat model will be valuable for the study of β-chemokine receptor antagonists as 
potential therapeutics for the treatment of AIDS. 
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FIGURE LEGENDS 
 
Figure 1.  Expression of feline CXCR4 and CCR5 as EGFP fusion proteins. AH927 cells 
were transduced with retroviral vectors carrying feline CXCR4.EGFP (b., e.), 
CCR5.EGFP (c., f.) or EGFP (a., d.) alone and selected in G418 (800μg/ml). EGFP 
expression was quantified by flow cytometry (a., b., c.) while sub-cellular localization 
was analysed by UV microscopy (d., e., f.). Histograms represent plots of fluorescence 
intensity (x-axis) vs. relative cell number (y-axis). 
 
Figure 2. Estimation of surface CXCR4 expression in transduced cells by flow cytometry. 
AH927 cells were transduced with vectors carrying feline CXCR4-EGFP (c.,d.), feline 
CCR5-EGFP (e.,f.) or EGFP alone (a.,b.). Two colour dot plots of EGFP expression (x-
axis) vs. CXCR4 expression (y-axis) (b.,d.,f.) compared with isotype-matched control 
(A,C,E).  Each dot plot represents 10,000 events. 
 
Figure 3.  Estimation of total surface CXCR4 expression in transduced AH927 cells by 
flow cytometry. AH927 cells stably transduced with pDONAI-based retroviral vectors 
bearing EGFP (E), feCXCR4.EGFP (FX4E) or feCCR5.EGFP (FR5E) were transduced 
again with a second series of pBabePuro vectors bearing feCXCR4 (FX4P), feCCR5 
(FR5P),  huCXCR4 (HX4P) or vector only (P) and selected in puromycin. Two colour 
dot plots of EGFP expression (x-axis) vs. surface CXCR4 expression (y-axis). Each dot 
plot represents 10,000 events. 
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Figure  4.  Enhanced expression of  human CXCR4 in cells transduced previously with 
feline CXCR4-EGFP (FX4E, (e., f.)) or CCR5-EGFP (FR5E, (c., d.)) or EGFP alone (E, 
(a., b.)). E, FX4E or FR5E cells were transduced with feline CXCR4 (FX4P, (a., c., e.) or 
human CXCR4 (HX4P, (b., d., f.) in the vector pbabepuro.  Human CXCR4-specific 
monoclonal antibody 12G5 was used to differentiate human and feline CXCR4. Two 
colour dot plots of EGFP expression (x-axis) vs. surface CXCR4 expression (y-axis). 
Each dot plot represents 10,000 events. 
 
Figure 5. Susceptibility of AH927 cells transduced with CXCR4 or CCR5 to cell-free 
virus infection with cell culture adapted (PETF14) or primary strains of FIV (GL8414) and 
to syncytium formation following transfection with expression vectors carrying the   
PETF14 or GL8414 env genes. Productive infection was measured by non-isotopic reverse 
transcriptase assay (absorbance 405nm), syncytium formation was scored + or -. Feline T 
cell line Mya-1 was included as a  control for infection with GL8414.  
 
Figure 6.  Syncytium formation in GHOST cells expressing feline or human chemokine 
receptors.  Expression vectors carrying primary (GL8414 or PPR) or cell culture adapted 
(PETF14 or GL8EK) env genes were transfected into GHOST cells expressing a range of 
feline or human chemokine receptors. Syncytium formation was assessed by light 
microscopy at 48 hours post transfection. Typical results for PETF14 are shown with 
scoring + or - (left panel), a summary of the results for all four env genes are shown (right 
panel).  
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Figure 7.  Flow cytometric analysis of CCR5 and CXCR4 expression on Ghost cell lines.  
Ghost cell lines X4, R5, X4R5 and X4R5R3 were stained with either anti-huCCR5 (R&D 
systems #45519) or anti-huCXCR4 (R&D systems #44708). Bound antibody was 
detected using PE-conjugated anti-mouse IgG. 10,000 events were collected for each 
sample. Histograms represent plots of fluorescence intensity (x-axis) vs. relative cell 
number (y-axis). 
 
Figure 8.  Detection of viral entry into chemokine receptor-expressing cell lines.  A. 
Ghost X4, R5, X4R5, X4R5R3 or vector-only control cells, or (B) AH927 FX4E, FR5E 
or E cells, were infected with PETF14 or GL8414 for 24 hours and the polymerase chain 
reaction was then used to detect viral (gag) or cellular (β-actin) DNA. Products were 
visualized by agarose gel electrophoresis and ethidium bromide staining. 
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